Cargando…

Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study

BACKGROUND: To quantify pharmacological effects on tremor in patients with essential tremor (ET) or Parkinson’s Disease (PD), laboratory-grade accelerometers have previously been used. Over the last years, consumer products such as smartphones and smartwatches have been increasingly applied to measu...

Descripción completa

Detalles Bibliográficos
Autores principales: van Brummelen, Emilie M. J., Ziagkos, Dimitrios, de Boon, Wadim M. I., Hart, Ellen P., Doll, Robert J., Huttunen, Teppo, Kolehmainen, Petteri, Groeneveld, Geert Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137336/
https://www.ncbi.nlm.nih.gov/pubmed/32280482
http://dx.doi.org/10.1186/s40734-020-00086-7
_version_ 1783518407447019520
author van Brummelen, Emilie M. J.
Ziagkos, Dimitrios
de Boon, Wadim M. I.
Hart, Ellen P.
Doll, Robert J.
Huttunen, Teppo
Kolehmainen, Petteri
Groeneveld, Geert Jan
author_facet van Brummelen, Emilie M. J.
Ziagkos, Dimitrios
de Boon, Wadim M. I.
Hart, Ellen P.
Doll, Robert J.
Huttunen, Teppo
Kolehmainen, Petteri
Groeneveld, Geert Jan
author_sort van Brummelen, Emilie M. J.
collection PubMed
description BACKGROUND: To quantify pharmacological effects on tremor in patients with essential tremor (ET) or Parkinson’s Disease (PD), laboratory-grade accelerometers have previously been used. Over the last years, consumer products such as smartphones and smartwatches have been increasingly applied to measure tremor in an easy way. However, it is unknown how the technical performance of these consumer product accelerometers (CPAs) compares to laboratory-grade accelerometers (LGA). This study was performed to compare the technical performance of CPAs with LGA to measure tremor in patients with Parkinson’s Disease (PD) and essential tremor (ET). METHODS: In ten patients with PD and ten with ET, tremor peak frequency and corresponding amplitude were measured with 7 different CPAs (Apple iPhone 7, Apple iPod Touch 5, Apple watch 2, Huawei Nexus 6P, Huawei watch, mbientlabMetaWear (MW) watch, mbientlab MW clip) and compared to a LGA (Biometrics ACL300) in resting and extended arm position. RESULTS: Both in PD and ET patients, the peak frequency of CPAs did not significantly differ from the LGA in terms of limits of agreement. For the amplitude at peak frequency, only the iPhone and MW watch performed comparable to the LGA in ET patients, while in PD patients all methods performed comparable except for the iPod Touch and Huawei Nexus. Amplitude was higher when measured with distally-located CPAs (Clip, iPhone, iPod) compared with proximally-located CPAs (all watches). The variability between subjects was higher than within subjects for frequency (25.1% vs. 13.4%) and amplitude measurement (331% vs. 53.6%). Resting arm position resulted in lower intra-individual variability for frequency and amplitude (13.4 and 53.5%) compared to extended arm position (17.8 and 58.1%). CONCLUSIONS: Peak frequencies of tremor could be measured with all tested CPAs, with similar performance as LGA. The amplitude measurements appeared to be driven by anatomical location of the device and can therefore not be compared. Our results show that the tested consumer products can be used for tremography, allowing at-home measurements, in particular in studies with a cross-over or intra-individual comparison design using the resting arm position. TRIAL REGISTRATION: This trial was registered in the Dutch Competent Authority (CCMO) database with number NL60672.058.17 on May 30th 2017.
format Online
Article
Text
id pubmed-7137336
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71373362020-04-11 Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study van Brummelen, Emilie M. J. Ziagkos, Dimitrios de Boon, Wadim M. I. Hart, Ellen P. Doll, Robert J. Huttunen, Teppo Kolehmainen, Petteri Groeneveld, Geert Jan J Clin Mov Disord Research Article BACKGROUND: To quantify pharmacological effects on tremor in patients with essential tremor (ET) or Parkinson’s Disease (PD), laboratory-grade accelerometers have previously been used. Over the last years, consumer products such as smartphones and smartwatches have been increasingly applied to measure tremor in an easy way. However, it is unknown how the technical performance of these consumer product accelerometers (CPAs) compares to laboratory-grade accelerometers (LGA). This study was performed to compare the technical performance of CPAs with LGA to measure tremor in patients with Parkinson’s Disease (PD) and essential tremor (ET). METHODS: In ten patients with PD and ten with ET, tremor peak frequency and corresponding amplitude were measured with 7 different CPAs (Apple iPhone 7, Apple iPod Touch 5, Apple watch 2, Huawei Nexus 6P, Huawei watch, mbientlabMetaWear (MW) watch, mbientlab MW clip) and compared to a LGA (Biometrics ACL300) in resting and extended arm position. RESULTS: Both in PD and ET patients, the peak frequency of CPAs did not significantly differ from the LGA in terms of limits of agreement. For the amplitude at peak frequency, only the iPhone and MW watch performed comparable to the LGA in ET patients, while in PD patients all methods performed comparable except for the iPod Touch and Huawei Nexus. Amplitude was higher when measured with distally-located CPAs (Clip, iPhone, iPod) compared with proximally-located CPAs (all watches). The variability between subjects was higher than within subjects for frequency (25.1% vs. 13.4%) and amplitude measurement (331% vs. 53.6%). Resting arm position resulted in lower intra-individual variability for frequency and amplitude (13.4 and 53.5%) compared to extended arm position (17.8 and 58.1%). CONCLUSIONS: Peak frequencies of tremor could be measured with all tested CPAs, with similar performance as LGA. The amplitude measurements appeared to be driven by anatomical location of the device and can therefore not be compared. Our results show that the tested consumer products can be used for tremography, allowing at-home measurements, in particular in studies with a cross-over or intra-individual comparison design using the resting arm position. TRIAL REGISTRATION: This trial was registered in the Dutch Competent Authority (CCMO) database with number NL60672.058.17 on May 30th 2017. BioMed Central 2020-04-07 /pmc/articles/PMC7137336/ /pubmed/32280482 http://dx.doi.org/10.1186/s40734-020-00086-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
van Brummelen, Emilie M. J.
Ziagkos, Dimitrios
de Boon, Wadim M. I.
Hart, Ellen P.
Doll, Robert J.
Huttunen, Teppo
Kolehmainen, Petteri
Groeneveld, Geert Jan
Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study
title Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study
title_full Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study
title_fullStr Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study
title_full_unstemmed Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study
title_short Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study
title_sort quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and parkinson’s disease: a comparative study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137336/
https://www.ncbi.nlm.nih.gov/pubmed/32280482
http://dx.doi.org/10.1186/s40734-020-00086-7
work_keys_str_mv AT vanbrummelenemiliemj quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT ziagkosdimitrios quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT deboonwadimmi quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT hartellenp quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT dollrobertj quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT huttunenteppo quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT kolehmainenpetteri quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy
AT groeneveldgeertjan quantificationoftremorusingconsumerproductaccelerometryisfeasibleinpatientswithessentialtremorandparkinsonsdiseaseacomparativestudy